GUERBET |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.4 EUR | +4.32% |
|
+10.65% | +91.79% |
| 26/04 | Guerbet: quarterly sales up by nearly 8 | CF |
| 25/04 | Guerbet SA Provides Earnings Guidance for the Year 2024 | CI |
| Sales 2024 * | 854M 914M 76.2B | Sales 2025 * | 918M 981M 81.86B | Capitalization | 470M 503M 41.95B |
|---|---|---|---|---|---|
| Net income 2024 * | 28M 29.94M 2.5B | Net income 2025 * | 40M 42.77M 3.57B | EV / Sales 2024 * | 0.91 x |
| Net Debt 2024 * | 308M 329M 27.46B | Net Debt 2025 * | 275M 294M 24.52B | EV / Sales 2025 * | 0.81 x |
| P/E ratio 2024 * |
16.2
x | P/E ratio 2025 * |
11.9
x | Employees | 2,920 |
| Yield 2024 * |
1.55% | Yield 2025 * |
1.78% | Free-Float | 43.67% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.32% | ||
| 1 week | +10.65% | ||
| Current month | +13.85% | ||
| 1 month | +9.20% | ||
| 3 months | +92.58% | ||
| 6 months | +125.30% | ||
| Current year | +91.79% |
1 week
32.30
38.75
1 month
31.7538.75
Current year
17.0238.75
1 year
15.4838.75
3 years
15.2845.65
5 years
15.2856.40
10 years
15.2890.64
| Managers | Title | Age | Since |
|---|---|---|---|
David Hale
CEO | Chief Executive Officer | 55 | 01/18/01 |
Jérôme Estampes
DFI | Director of Finance/CFO | - | 01/19/01 |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Thibault Viort
BRD | Director/Board Member | 51 | 19/17/19 |
Pascale Auger
BRD | Director/Board Member | 61 | 26/23/26 |
Mark Fouquet
BRD | Director/Board Member | 64 | 23/14/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 37.4 | +4.32% | 62,402 |
| 25/24/25 | 35.85 | +0.99% | 17,683 |
| 24/24/24 | 35.5 | +0.71% | 30,742 |
| 23/24/23 | 35.25 | +2.62% | 11,790 |
| 22/24/22 | 34.35 | +1.63% | 13,517 |
Real-time Euronext Paris, April 26, 2024 at 09:05 pm IST
More quotes
Guerbet is a European leader in producing and selling contrast products for medical imaging. The group's products make it possible to visualize different organs and the lymphatic and vascular systems of the human body by making them opaque. Net sales break down by product family as follows:
- X-ray imaging products (55.4%);
- MRI products (32.7%);
- other (11.9%): contrast products for echography and nuclear medicine, fine chemicals products.
At the end of 2023 the group had 8 production sites located in France (4), the United States (2), Ireland and Brazil.
Europe accounts for 39.7% of net sales.
Calendar
24/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
37.4
EUR
Average target price
39.3
EUR
Spread / Average Target
+5.08%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +91.79% | 502M | |
| -5.77% | 14.68B | |
| -40.71% | 2.71B | |
| -12.92% | 2.44B | |
| -8.78% | 1.51B | |
| -.--% | 1.12B | |
| +40.66% | 518M | |
| +1.67% | 183M | |
| -.--% | 168M | |
| -29.34% | 161M |
- Stock Market
- Equities
- GBT Stock
